Last quarter, biotech stock performance remained lackluster and financing in the sector (∼$12 billion) lagged behind the first and fourth quarters of 2006. Venture capital funding, however, reached a new benchmark, surpassing $1.9 billion—up by half in the US; Asia also witnessed an uptick, whereas Europe performed poorly. The amount raised in initial public offerings raising (IPOs) held steady, with European IPOs raising the most funds for the second successive quarter.
Source: Multex, BioCentury
Source: BioCentury
Source: BioCentury
Source: BioCentury
Source: BioCentury, Recombinant Capital.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lawrence, S. VC funding hits high in Q1. Nat Biotechnol 25, 496 (2007). https://doi.org/10.1038/nbt0507-496
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0507-496
